Immunization in cancer patients: Where we stand

Robin, Christine; Beckerich, Florence; Cordonnier, Catherine

doi:10.1016/j.phrs.2014.10.002

Cited by 21 publications

(20 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prospective trials on vaccination in specific diseases should be encouraged, taking into account the timing of the therapeutic program of the underlying disease. 324 Although the role of the pharmaceutical industry is of the utmost importance to produce new tests and new drugs and support large, well-designed trials, more academic involvement is essential for translational research, epidemiology, and prospective randomized trials within the field.…”

Section: Section 8 Infections In Hematologymentioning

confidence: 99%

The European Hematology Association Roadmap for European Hematology Research: a consensus document

et al. 2016

View full text Add to dashboard Cite

T he European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

show abstract

Section: Section 8 Infections In Hematologymentioning

confidence: 99%

The European Hematology Association Roadmap for European Hematology Research: a consensus document

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Interestingly, in this population, antibody responses to PSV23 positively correlate with hematologic response to chemotherapy [85]. The conjugated 13-valent pneumococcal vaccination (PCV13) depends more heavily upon T-cell responses, and remains more immunogenic in many immunocompromised cancer populations [86-88]. …”

Section: Introductionmentioning

confidence: 99%

Bacterial Pneumonia in Patients with Cancer

Wong¹,

Evans

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

Synopsis Bacterial pneumonias exact unacceptable morbidity upon patients with cancer. While the risk is often most pronounced amongst patients with treatment-induced cytopenias, the numerous contributors to life-threatening pneumonias in cancer populations range from derangements of lung architecture and swallow function to complex immune defects associated with cytotoxic therapies and graft-vs.-host disease. These structural and immunologic abnormalities often make the diagnosis of pneumonia challenging in cancer patients and impact the composition and duration of therapy. This manuscript addresses the host factors that contribute to pneumonia susceptibility, summarizes diagnostic recommendations, and reviews current guidelines for management of bacterial pneumonia in cancer patients.

show abstract

“…Vaccination programmes in cancer patients represent another intriguing topic discussed in this issue [5]. In their literature revision, Dr. Robin et al tackled several important points, including the rationale of implementing immunisation programmes in cancer patients and concerns about reduced immune response.…”

mentioning

confidence: 99%